<scp>Glucagon‐like</scp> peptide‐1 receptor agonists in the era of <scp>COVID</scp>‐19: Friend or foe?

Belančić, Andrej; Kresović, Andrea; Dijan, Marija

doi:10.1111/cob.12439

Cited by 26 publications

(37 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[15] In addition to stimulating postprandial insulin secretion, GLP1-RA also seems to have beneficial properties such antiinflammatory, anti-obesogenic, pulmonary protective effects and gut microbiome modulating effects. [16] Furthermore, an experimental study on rats showed that the use of GLP1-RA (liraglutide) was capable to stimulate pulmonary ACE2 expression, an enzyme that has been demonstrated to oppose the pathway that is responsible for the progression of acute respiratory distress syndrome (ARDS), including the one caused by SARS-CoV-2 infection. [17,18] However, the evidences regarding benefit of GLP-1RA in Covid-19 patients are still unclear.…”

Section: Introductionmentioning

confidence: 99%

Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): A systematic review, meta-analysis, and meta-regression

Hariyanto

Intan

Hananto

et al. 2021

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

Aims GLP-1RA has many beneficial properties, including anti-inflammatory, anti-obesogenic, pulmonary protective effects as well as beneficial impact on gut microbiome. However, the evidence regarding the benefit of GLP-1RA in Covid-19 patients with diabetes is still unclear. This study sought to analyze the benefit of pre-admission use of GLP-1RA in altering the mortality outcomes of coronavirus disease 2019 (Covid-19) patients with diabetes mellitus. Methods Using specific keywords, we comprehensively searched the potential articles on PubMed, Europe PMC, and medRxiv database until June 12 th , 2021. All published studies on Covid-19 and GLP-1RA were retrieved. Statistical analysis was conducted using Review Manager 5.4 and Comprehensive Meta-Analysis version 3 software. Results A total of 9 studies with 19,660 diabetes mellitus patients who were infected by SARS-CoV-2 were included in the meta-analysis. Our data suggested that pre-admission use of GLP-1RA was associated with reduction in mortality rate from Covid-19 in patients with diabetes mellitus (OR 0.53; 95%CI: 0.43 – 0.66, p <0.00001, I 2 = 0%, random-effect modelling). Further analysis showed that the associations were not influenced by age ( p =0.213), gender (p=0.421), hypertension (p=0.131), cardiovascular disease (p=0.293), nor the use of metformin (p=0.189) and insulin (p=0.117). Conclusions Our study suggests that pre-admission use of GLP-1RA may offer beneficial effects on Covid-19 mortality in patients with diabetes mellitus. However, more randomized clinical trials are required to confirm this conclusion.

show abstract

Section: Introductionmentioning

confidence: 99%

Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): A systematic review, meta-analysis, and meta-regression

Hariyanto

Intan

Hananto

et al. 2021

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

show abstract

“…A previous study speculated that GLP-1R agonists did not contribute to the recovery of patients with COVID-19 [ 46 ]. On the other hand, GLP-1R agonist-associated ACE2 respiratory upregulation is infrequent and shown in few animal studies only [ 47 ]. GLP-1R agonists have powerful glucose-lowering and weight loss effects [ 2 , 47 ].…”

Section: Drugs Interact With Ace2 and Nhementioning

confidence: 99%

“…On the other hand, GLP-1R agonist-associated ACE2 respiratory upregulation is infrequent and shown in few animal studies only [ 47 ]. GLP-1R agonists have powerful glucose-lowering and weight loss effects [ 2 , 47 ]. Besides, they may have anti-inflammatory and pulmonary protective effects and a beneficial impact on gut microbiome composition.…”

Section: Drugs Interact With Ace2 and Nhementioning

confidence: 99%

See 1 more Smart Citation

Effects of the Na⁺/H⁺ Ion Exchanger on Susceptibility to COVID-19 and the Course of the Disease

Cüre¹,

Cüre²

2021

J Renin Angiotensin Aldosterone Syst

View full text Add to dashboard Cite

The Na+/H+ ion exchanger (NHE) pumps Na+ inward the cell and H+ ion outside the cell. NHE activity increases in response to a decrease in intracellular pH, and it maintains intracellular pH in a narrow range. Patients with obesity, diabetes, and hypertension and the elderly are prone to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. The angiotensin II (Ang II) level is high in chronic diseases such as diabetes, hypertension, and obesity. Ang II is the main stimulator of NHE, and an increased Ang II level causes prolonged NHE activation in these patients. The long-term increase in NHE activity causes H+ ions to leave the cell in patients with diabetes, hypertension, and obesity. Increasing H+ ions outside the cell lead to an increase in oxidative stress and reactive oxygen species. H+ ion flows into the cell due to the increased oxidative stress. This vicious circle causes intracellular pH to drop. Although NHE is activated when intracellular pH decreases, there is prolonged NHE activation in chronic diseases such as aforementioned. Novel coronavirus disease 2019 (COVID-19) progression may be more severe and mortal in these patients. SARS-CoV-2 readily invades the cell at low intracellular pH and causes infection. The renin-angiotensin system and NHE play a vital role in regulating intracellular pH. The reduction of NHE activity or its prolonged activation may cause susceptibility to SARS-CoV-2 infection by lowering intracellular pH in patients with diabetes, hypertension, and obesity. Prolonged NHE activation in these patients with COVID-19 may worsen the course of the disease. Scientists continue to investigate the mechanism of the disease and the factors that affect its clinical progression.

show abstract

“…These drugs have been initially used in diabetes treatment but now are also used in the management of obesity itself. GLP-1RAs exhibit anti-inflammatory properties, exert pulmonary protective effects, and have a beneficial influence on, gut microbiome [ 23 ]. However, in some animal studies, GLP-1RAs increased ACE-2 levels promoting SARS-CoV-2 infection [ 24 ].…”

Section: Main Textmentioning

confidence: 99%

The vicious cycle: a history of obesity and COVID-19

Bil

Możeńska

2021

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Recently, we face a surge in the fast-forward Coronavirus Disease 2019 (COVID-19) pandemic with nearly 170 million confirmed cases and almost 3.5 million confirmed deaths at the end of May 2021. Obesity, also known as the pandemic of the 21st century, has been evolving as an adverse prognostic marker. Obesity is associated with a higher risk of being SARS-CoV-2-positive (46%), as well as hospitalization (113%) and death (48%) due to COVID-19. It is especially true for subjects with morbid obesity. Also, observational studies suggest that in the case of COVID-19, no favorable “obesity paradox” is observed. Therefore, it is postulated to introduce a new entity, i.e., coronavirus disease-related cardiometabolic syndrome (CIRCS). In theory, it applies to all stages of COVID-19, i.e., prevention, acute proceedings (from COVID-19 diagnosis to resolution or three months), and long-term outcomes. Consequently, lifestyle changes, glycemic control, and regulation of the renin-angiotensin-aldosterone pathway have crucial implications for preventing and managing subjects with COVID-19. Finally, it is crucial to use cardioprotective drugs such as angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers and statins. Nevertheless, there is the need to conduct prospective studies and registries better to evaluate the issue of obesity in COVID-19 patients.

show abstract

Glucagon‐like peptide‐1 receptor agonists in the era of COVID‐19: Friend or foe?

Cited by 26 publications

References 71 publications

Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): A systematic review, meta-analysis, and meta-regression

Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): A systematic review, meta-analysis, and meta-regression

Effects of the Na⁺/H⁺ Ion Exchanger on Susceptibility to COVID-19 and the Course of the Disease

The vicious cycle: a history of obesity and COVID-19

Contact Info

Product

Resources

About

Glucagon‐like peptide‐1 receptor agonists in the era of COVID‐19: Friend or foe?

Cited by 26 publications

References 71 publications

Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): A systematic review, meta-analysis, and meta-regression

Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): A systematic review, meta-analysis, and meta-regression

Effects of the Na+/H+ Ion Exchanger on Susceptibility to COVID-19 and the Course of the Disease

The vicious cycle: a history of obesity and COVID-19

Contact Info

Product

Resources

About

Effects of the Na⁺/H⁺ Ion Exchanger on Susceptibility to COVID-19 and the Course of the Disease